RAAB MICHAEL 4

What Happened

• Michael Raab, a director of Tempest Therapeutics (TPST), received a grant/award on 2026-01-27 covering 1,230 derivative shares. The filing reports an acquisition price of $0.00, indicating no cash was paid at grant and the award is a derivative equity grant rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-01-27; Form 4 filed: 2026-01-28.
• Transaction type: Award/Grant of a derivative security (code A). Reported price: $0.00.
• Shares reported in the grant: 1,230.
• Vesting: The footnote states the shares underlying the option will vest in full on the earlier of (i) January 27, 2027, or (ii) the issuer's 2026 annual meeting, subject to Raab’s continuous service through that date.
• Shares owned after the transaction: not specified in the filing.
• Filing timeliness: filed the day after the transaction (no late filing indicated).

Context

• This was a compensation-style equity award (derivative/option-like) with time-based vesting — not an immediate purchase or sale. Such grants are common for directors and reflect compensation, not necessarily a direct market signal. No exercise or sale occurred in this filing.